Key Points – Record Q2 performance: Revenue rose 9.8% year over year on a constant-currency basis to $391 million, while adjusted EPS increased to $1.26 from $1.05, supported by double-digit growth in Cardiopulmonary and Epilepsy. – 2026 outlook raised: LivaNova increased its…
ll-year revenue-growth guidance to 8%–9% and adjusted EPS guidance to $4.30–$4.40, citing stronger Cardiopulmonary demand, pricing and reimbursement momentum in Epilepsy, and improved execution. – Investment weighs on cash flow: The company raised capital-spending guidance to $135 million and cut adjusted free-cash-flow guidance to $140 million–$160 million as it invests in manufacturing capacity, innovation and IT infrastructure; a new oxygenator line is expected to materially increase output in 2027. LivaNova (NASDAQ:LIVN) reported record quarterly revenue and adjusted earnings per share for the second quarter of 2026, citing double-digit reported growth across its Cardiopulmonary and Epilepsy businesses
The company raised its full-year revenue and adjusted EPS outlook while reducing its adjusted free-cash-flow forecast to account for increased investment in manufacturing capacity, innovation and IT infrastructure. Second-quarter revenue totaled $391 million, up 9.8% on a constant-currency basis from a year earlier. Foreign exchange provided an approximately $3 million, or 1%, year-over-year benefit.
Adjusted diluted EPS rose to $1.26 from $1.05 in the second quarter of 2025, aided by higher revenue and a one-time tariff refund. “We delivered a strong quarter of double-digit reported revenue growth with strength across all regions, driven by robust performance in our Cardiopulmonary and Epilepsy businesses,” CEO Vladimir Makatsaria said. Cardiopulmonary Growth and Oxygenator Supply Plans Cardiopulmonary revenue was $222 million, an increase of 10% from the prior-year quarter, led by growth in Europe. Heart-lung machine revenue grew in the mid-teens, driven by increased placements of the…